ALB and plasma cell myeloma: The ability to bind to human serum albumin extends the plasma half-life of MP0250 to 12 days.62 As monotherapy and in combination with bortezomib, MP0250 inhibits myeloma cell migration, invasion and bone destruction in an orthotopic mouse model of multiple myeloma.63 Phase I interim results showed that MP0250 monotherapy was well tolerated, and a maximum tolerated dose had not been reached.